Impact of blood sampling on the circulating matrix metalloproteinases 1, 2, 3, 7, 8, and 9.
Jung K, Klotzek S, Stephan C, Mannello F, Lein M
Purpose
Conclusion
Studies (1)
Purpose
The purpose of this study was to determine if blood matrix metalloproteinase (MMP) levels differ as a result of anticoagulant type or the presence of a coagulant accelerator.
Summary of Findings
In general, MMP concentrations were higher in serum than in plasma specimens. In comparison to additive-free serum, serum treated with a coagulant accelerator (kaolin-coated granules) displayed significantly higher MMP-1, -8, and -9 levels. Conversely, levels of MMP-2, -3, and -7 were comparable among serum with and without additives as well as sodium citrate or lithium heparin treated plasma specimens.
Biospecimens
FluidPlasmaFluidSerumFluidBloodPreservation Types
FrozenDiagnoses
NormalPlatforms
ProteinAutomated electrophoresis/BioanalyzerPre-analytical Factors
Classification Pre-Analytical Factor Value(s) Biospecimen Acquisition Anticoagulant Lithium heparinNonePotassium EDTASodium citrateBiospecimen Aliquots and Components Blood and blood products PlasmaSerum